BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Brainstorm Cell Therapeutics, a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.

The European Patent office granted patent No. 3105587 titled ‘Method of Qualifying of Cells‘ for a method of qualifying whether a cell population is a suitable therapeutic for treating ALS. The patent also grants claims for an isolated population of mesenchymal stem cells for use in treating ALS.

The Australian patent Office granted patent No. 2019252987 titled ‘Cell-Type Specific Exosomes and Use Thereof’ for an isolated Exosomes population derived from MSC-NTF cells as well as a pharmaceutical composition for the treatment of neurodegenerative diseases.

The Israel Patent Office announced the allowance of the same claims for application No. 277447 with an Acceptance date on December 01, 2023.

“We are committed to fortifying our technological advancements with robust intellectual property strategies,” stated BrainStorm’s CEO, Chaim Lebovits. “The recent acquisition of the European patent for our unique MSC-NTF cell population marks an important step in safeguarding our proprietary NurOwn technology, particularly for ALS treatment. The Australian patent, which is our inaugural grant for the specialized MSC-NTF cell exosomes, represents a pivotal achievement in the evolution of our exosome technology, meticulously crafted by the Brainstorm research team. Securing this European patent, alongside our existing patents in the US, CanadaIsraelBrazil, and Japan, enhances our capability to forge new global commercial partnerships, further expanding the reach of NurOwn.”

SourcePR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *